Personal HistoryAmber Beitelshees received her PharmD degree from the University of Florida in 2001. She then completed a residency in Pharmacy Practice at the University of Illinois Medical Center at Chicago. In 2005, Dr. Beitelshees completed her postdoctoral fellowship in Cardiovascular Pharmacogenomics and Master of Public Health degree in epidemiology. After serving on the faculty at Washington University in St. Louis School of Medicine, she returned to the University of Florida as an Assistant Professor in the Department of Pharmacy Practice. In November of 2008, Dr. Beitelshees was recruited to the University of Maryland Division of Endocrinology, Diabetes and Nutrition.
Research InterestsMy research is aimed at improving outcomes in the treatment and prevention of cardiovascular disease and diabetes. By understanding the genetic determinants of variability in drug response, we hope to optimize individuals' drug therapy more efficiently and effectively. We are particularly interested in determining how variability in genes involved in lipid and glucose metabolism can be used to predict improved safety and efficacy of the chronic medications used to treat cardiovascular disease. My lab utilizes genetic epidemiology, clinical pharmacology, and functional genomics to address these questions.
Cavallari LH, Fashingbauer, LA, Beitelshees AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 2004;24(6):750-756.
Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76(6):536-44.
Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J 2004;4:354-8.
Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetic studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann of Pharmacother 2006; 40(4):639-44.
Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arrant CB, Wessel TR, Schofield RS. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 2006;33(5):258-63.
Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomic studies. Am J Health Syst Pharm 2006;63(21):2101-10.
Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy 2006;26(9):1247-54.
Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J 2006;6(3):174-8.
Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol Sci 2006;27(9):498-502.
Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Scofield RS, Hamilton KK, Patterson JH, Adams KF, Hill JA, Aranda JM, Johnson JA. Synergistic polymorphisms of the beta1- and alpha2c-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacoget Genom 2007; 17(4):277-82.
Zineh I, Beitelshees AL, Haller MJ. NOS3 Polymorphisms are Associated with Arterial Stiffness in Children with Type 1 Diabetes. Diabetes Care 2007;30: 689-693.
Aquilante CL, Beitelshees AL, Zineh I. Predictors of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48-52
Gong Y, Beitelshees AL, Wessel J, Langaee TY, Schork NJ, Johnson JA. SNP discovery and haplotype analysis of BK channel beta-1 subunit. Pharmacoget Genom 2007;17(4):267-75.
Beitelshees AL, Gong Y, Schork NJ, Cooper-DeHoff RM, Langaee TY, Shriver MD, Pepine CJ, Johnson JA. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genom 2007;17(9):719-29.
Gerhard T, Gong Y, Beitelshees AL, Mao X, Lobmeyer MT, Cooper-DeHoff RM, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from INVEST-GENES. Am Heart J 2008; 156:397-404.
Zineh I, Beitelshees AL, Welder GJ, Hou W, Nasser C, Wu J, Cresci S, Province MA, Spertus JA. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS ONE 2008;3(9)e3117.
Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey KR, Cooper-DeHoff RM, Gums JG, Curry RW, Gong Y, Beitelshees AL, Schwartz GL, Turner ST. Pharmacogenomics of Antihypertensive drugs: Rationale and Design of the Pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J, in press.
Zineh I, Beitelshees AL, Silverstein JH, Haller MJ. Serum MCP-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care, in press.